SG Americas Securities LLC Acquires 30,108 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

SG Americas Securities LLC raised its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 207.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,603 shares of the medical technology company’s stock after purchasing an additional 30,108 shares during the period. SG Americas Securities LLC’s holdings in Alphatec were worth $248,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Alphatec by 1.2% during the first quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock valued at $75,278,000 after acquiring an additional 64,648 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Alphatec by 65.2% in the second quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock worth $33,365,000 after purchasing an additional 1,260,137 shares during the last quarter. Fred Alger Management LLC boosted its holdings in Alphatec by 0.8% in the second quarter. Fred Alger Management LLC now owns 2,638,303 shares of the medical technology company’s stock worth $27,570,000 after purchasing an additional 21,078 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Alphatec by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,630,244 shares of the medical technology company’s stock worth $27,486,000 after purchasing an additional 505,202 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Alphatec by 93.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,451,499 shares of the medical technology company’s stock worth $21,932,000 after purchasing an additional 702,950 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Insider Activity at Alphatec

In related news, Director David M. Demski acquired 50,000 shares of the stock in a transaction dated Wednesday, August 21st. The stock was acquired at an average cost of $5.67 per share, with a total value of $283,500.00. Following the purchase, the director now directly owns 288,441 shares of the company’s stock, valued at approximately $1,635,460.47. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 22.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ATEC shares. Barclays began coverage on shares of Alphatec in a report on Monday, July 8th. They issued an “overweight” rating and a $19.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Lake Street Capital cut their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Stifel Nicolaus lowered their price objective on Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Alphatec Price Performance

Shares of Alphatec stock opened at $5.36 on Tuesday. The firm has a market cap of $749.78 million, a PE ratio of -3.60 and a beta of 1.39. The stock has a 50 day moving average of $5.83 and a 200 day moving average of $9.07. The company has a current ratio of 2.22, a quick ratio of 1.21 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.03). Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The business had revenue of $145.57 million during the quarter, compared to the consensus estimate of $144.55 million. During the same quarter in the prior year, the firm posted ($0.43) EPS. The company’s revenue for the quarter was up 24.5% on a year-over-year basis. On average, research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.